tert-butyl N-[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(4S,5S,7S)-5-hydroxy-2,8-dimethyl-7-[[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]oxymethyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate | 112374-81-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: tert-butyl N-[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(4S,5S,7S)-5-hydroxy-2,8-dimethyl-7-[[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]oxymethyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 112374-81-9
• 化学式: C₆₅H₈₉N₉O₁₁S
• 分子量: 1204.54
• InChiKey: ZEDCCZZWVKLRRL-JELBXJDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.01
• 重原子数：
  86.0
• 可旋转键数：
  30.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  269.35
• 氢给体数：
  6.0
• 氢受体数：
  14.0

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(4S,5S,7S)-5-hydroxy-2,8-dimethyl-7-[[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]oxymethyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate 在 1-羟基苯并三唑 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 144.0h， 以59%的产率得到tert-butyl N-[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(4S,5S,7S)-5-hydroxy-2,8-dimethyl-7-[[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]oxymethyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate
  参考文献：
  名称：

  Renin inhibitors containing .psi.[CH2O] pseudopeptide inserts

  摘要：

  Renin inhibitors 2-4 with the D-Lys renin inhibitory peptide (RIP) sequence, but containing Leu psi[CH2O]Ala (2), Leu psi[CH2O]Val (3), and Leu psi[CH2O]Leu (4) at the P1-P1' site, were of a comparable potency to RIP. N-Terminal Boc-protected inhibitors containing Pro psi[CH2O]Phe in positions P4-P3 were potent inhibitors of renin, with Boc-Phe-Pro psi[CH2O]Phe-His-Leu psi[CH(OH)CH2]Val-Ile-(2-aminomethyl) pyridine (17) having an IC50 of 1.6 X 10(-9) M.

  DOI：

  10.1021/jm00398a029
• 作为产物：
  描述：

  (2S,4S,5S)-5-Amino-4-(tert-butyl-dimethyl-silanyloxy)-2-isopropyl-7-methyl-octanoic acid {(1S,2S)-2-methyl-1-[(pyridin-2-ylmethyl)-carbamoyl]-butyl}-amide 在 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 tert-butyl N-[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(4S,5S,7S)-5-hydroxy-2,8-dimethyl-7-[[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]oxymethyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamate
  参考文献：
  名称：

  Renin inhibitors containing .psi.[CH2O] pseudopeptide inserts

  摘要：

  Renin inhibitors 2-4 with the D-Lys renin inhibitory peptide (RIP) sequence, but containing Leu psi[CH2O]Ala (2), Leu psi[CH2O]Val (3), and Leu psi[CH2O]Leu (4) at the P1-P1' site, were of a comparable potency to RIP. N-Terminal Boc-protected inhibitors containing Pro psi[CH2O]Phe in positions P4-P3 were potent inhibitors of renin, with Boc-Phe-Pro psi[CH2O]Phe-His-Leu psi[CH(OH)CH2]Val-Ile-(2-aminomethyl) pyridine (17) having an IC50 of 1.6 X 10(-9) M.

  DOI：

  10.1021/jm00398a029

文献信息

• TENBRINK, RUTH E.;PALS, DONALD T.;HARRIS, DOUGLAS W.;JOHNSON, GARLAND A., J. MED. CHEM., 31,(1988) N 3, 671-677
  作者：TENBRINK, RUTH E.、PALS, DONALD T.、HARRIS, DOUGLAS W.、JOHNSON, GARLAND A.

  DOI：——

  日期：——